JP6817073B2 - セロトニン受容体を標的にする化合物および方法 - Google Patents
セロトニン受容体を標的にする化合物および方法 Download PDFInfo
- Publication number
- JP6817073B2 JP6817073B2 JP2016568912A JP2016568912A JP6817073B2 JP 6817073 B2 JP6817073 B2 JP 6817073B2 JP 2016568912 A JP2016568912 A JP 2016568912A JP 2016568912 A JP2016568912 A JP 2016568912A JP 6817073 B2 JP6817073 B2 JP 6817073B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- receptors
- receptor
- less
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000286P | 2014-05-19 | 2014-05-19 | |
| US62/000,286 | 2014-05-19 | ||
| PCT/US2015/031523 WO2015179366A1 (en) | 2014-05-19 | 2015-05-19 | Serotonin receptor-targeting compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521367A JP2017521367A (ja) | 2017-08-03 |
| JP2017521367A5 JP2017521367A5 (enExample) | 2018-06-28 |
| JP6817073B2 true JP6817073B2 (ja) | 2021-01-20 |
Family
ID=54554616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568912A Active JP6817073B2 (ja) | 2014-05-19 | 2015-05-19 | セロトニン受容体を標的にする化合物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11021435B2 (enExample) |
| EP (1) | EP3145906B1 (enExample) |
| JP (1) | JP6817073B2 (enExample) |
| CN (1) | CN106573872B (enExample) |
| BR (1) | BR112016027096B1 (enExample) |
| ES (1) | ES2967976T3 (enExample) |
| WO (1) | WO2015179366A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3297979B1 (en) * | 2015-05-19 | 2024-11-20 | Northeastern University | Compounds and methods for modulating serotonin receptors in the periphery |
| CN108794308B (zh) * | 2017-04-27 | 2021-07-20 | 北京大学深圳研究生院 | 1,2,3,4-四氢萘类化合物及其制备方法和应用 |
| KR20220122602A (ko) * | 2019-10-23 | 2022-09-02 | 맵라이트 세라퓨틱스, 인크. | 자폐 스펙트럼 장애의 증상을 치료하는 방법 |
| KR20230073197A (ko) * | 2020-08-19 | 2023-05-25 | 노스이스턴 유니버시티 | 세로토닌 수용체 조절제 |
| CN117730073A (zh) * | 2021-07-14 | 2024-03-19 | 东北大学 | 血清素5-ht2a、5-ht2b和5-ht2c受体反向激动剂 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| GB9509156D0 (en) * | 1995-05-05 | 1995-06-28 | Sandoz Ltd | Organic compounds |
| ES2219679T3 (es) | 1995-10-18 | 2004-12-01 | Akzo Nobel N.V. | Vacuna de combinacion contra la enfermedad de newcastle. |
| US20030008880A1 (en) * | 2001-05-02 | 2003-01-09 | Pfizer Inc. | 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity |
| EP1956006A1 (en) * | 2007-02-06 | 2008-08-13 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands |
| EP1975161A1 (en) * | 2007-03-28 | 2008-10-01 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments |
| WO2008154044A1 (en) * | 2007-06-15 | 2008-12-18 | University Of Florida Research Foundation | Therapeutic compounds and methods of use |
| US8586634B2 (en) | 2007-06-15 | 2013-11-19 | University Of Florida Research Foundation, Inc. | Therapeutic compounds |
| WO2009061436A1 (en) * | 2007-11-06 | 2009-05-14 | University Of Florida Research Foundation | Compound for activating 5-ht2c receptors in combination with an amphetamine compound |
| US9024071B2 (en) * | 2009-05-05 | 2015-05-05 | University Of Florida Research Foundation, Inc. | Therapeutic compounds |
-
2015
- 2015-05-19 US US15/311,905 patent/US11021435B2/en active Active
- 2015-05-19 CN CN201580039372.8A patent/CN106573872B/zh active Active
- 2015-05-19 WO PCT/US2015/031523 patent/WO2015179366A1/en not_active Ceased
- 2015-05-19 EP EP15796940.3A patent/EP3145906B1/en active Active
- 2015-05-19 ES ES15796940T patent/ES2967976T3/es active Active
- 2015-05-19 BR BR112016027096-7A patent/BR112016027096B1/pt active IP Right Grant
- 2015-05-19 JP JP2016568912A patent/JP6817073B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016027096A2 (pt) | 2018-07-10 |
| US11021435B2 (en) | 2021-06-01 |
| EP3145906B1 (en) | 2023-10-04 |
| ES2967976T3 (es) | 2024-05-06 |
| US20170081273A1 (en) | 2017-03-23 |
| EP3145906A4 (en) | 2018-01-24 |
| EP3145906A1 (en) | 2017-03-29 |
| JP2017521367A (ja) | 2017-08-03 |
| CN106573872B (zh) | 2021-07-20 |
| BR112016027096B1 (pt) | 2023-04-11 |
| WO2015179366A1 (en) | 2015-11-26 |
| CN106573872A (zh) | 2017-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6817073B2 (ja) | セロトニン受容体を標的にする化合物および方法 | |
| US11111210B2 (en) | Phenyl cyclohexanone derivatives and methods of making and using them | |
| IL298769A (en) | Benzofuran compounds are useful for mental disorders or mental enhancement | |
| WO2017087858A1 (en) | Pyrazole compounds and methods of making and using same | |
| HUE030081T2 (en) | Heterocyclic benzodioxole or benzodioxepine compounds as phosphodiesterase inhibitors | |
| TW201002701A (en) | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | |
| WO2007069565A1 (ja) | 二環式複素環化合物 | |
| EP3697781B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| MX2015003637A (es) | Piridinonas biciclicas novedosas. | |
| AU2019216492A1 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
| JP2023530715A (ja) | アリールスルホニル誘導体及びムスカリン性アセチルコリン受容体m5阻害剤としてのその使用 | |
| TW200808784A (en) | Substituted phenyl methanone derivatives | |
| Banister et al. | 7-Azabicyclo [2.2. 1] heptane as a scaffold for the development of selective sigma-2 (σ2) receptor ligands | |
| TW202517609A (zh) | 氘化有機化合物及其用途(二) | |
| Llabrés et al. | Molecular basis of the selective binding of MDMA enantiomers to the alpha4beta2 nicotinic receptor subtype: synthesis, pharmacological evaluation and mechanistic studies | |
| US20240067611A1 (en) | Phenyl cyclohexanone derivatives and methods of making and using them | |
| HK1236024B (en) | Serotonin receptor-targeting compounds | |
| HK1236024A1 (en) | Serotonin receptor-targeting compounds | |
| CN108727416A (zh) | 三环杂芳香体系酰胺衍生物及其制备和用途 | |
| ES2892175T3 (es) | Moduladores de los receptores NMDA, composiciones que los incluyen y uso de dichos compuestos en el tratamiento de enfermedades que implican al sistema nervioso central | |
| US11827606B2 (en) | Phenyl cyclohexanone derivatives and methods of making and using them | |
| CN109890798A (zh) | 用于治疗cns病症的羟基去甲氯胺酮衍生物 | |
| US20230348358A1 (en) | Serotonin Receptor Modulators | |
| WO2023150526A1 (en) | Competitive and noncompetitive octahydrocyclopenta[c]pyrrole inhibitors of the muscarinic acetylcholine receptor m5 | |
| RS67052B1 (sr) | Vmat2 inhibitori i postupci primene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180518 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190509 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200204 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200501 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200703 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201102 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201124 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201224 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6817073 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |